Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. / Pedersen, Nadja Højgaard; Sørensen, Jennifer Astrup; Ghazanfar, Misbah Noshela; Zhang, Ditte Georgina; Vestergaard, Christian; Thomsen, Simon Francis.
I: International Journal of Molecular Sciences, Bind 24, Nr. 14, 11328, 2023, s. 1.14.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
AU - Pedersen, Nadja Højgaard
AU - Sørensen, Jennifer Astrup
AU - Ghazanfar, Misbah Noshela
AU - Zhang, Ditte Georgina
AU - Vestergaard, Christian
AU - Thomsen, Simon Francis
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023
Y1 - 2023
N2 - Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and these are also being investigated as potential biomarkers in the diagnosis and management of the disease. As of now the only assessment tools available for treatment response are patient reported outcomes (PROs). Although these tools are both validated and widely used, they leave a desire for more objective measurements. A biomarker is a broad subcategory of observations that can be used as an accurate, reproducible, and objective indicator of clinically relevant outcomes. This could be normal biological or pathogenic processes, or a response to an intervention or exposure, e.g., treatment response. Herein we provide an overview of biomarkers for CU, with a focus on prognostic biomarkers for treatment response to omalizumab, thereby potentially aiding physicians in personalizing treatments.
AB - Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and these are also being investigated as potential biomarkers in the diagnosis and management of the disease. As of now the only assessment tools available for treatment response are patient reported outcomes (PROs). Although these tools are both validated and widely used, they leave a desire for more objective measurements. A biomarker is a broad subcategory of observations that can be used as an accurate, reproducible, and objective indicator of clinically relevant outcomes. This could be normal biological or pathogenic processes, or a response to an intervention or exposure, e.g., treatment response. Herein we provide an overview of biomarkers for CU, with a focus on prognostic biomarkers for treatment response to omalizumab, thereby potentially aiding physicians in personalizing treatments.
KW - anti-IgE
KW - biomarkers
KW - chronic spontaneous urticaria
KW - chronic urticaria
KW - omalizumab
KW - treatment response
UR - http://www.scopus.com/inward/record.url?scp=85165962673&partnerID=8YFLogxK
U2 - 10.3390/ijms241411328
DO - 10.3390/ijms241411328
M3 - Review
C2 - 37511088
AN - SCOPUS:85165962673
VL - 24
SP - 1.14
JO - International Journal of Molecular Sciences (Online)
JF - International Journal of Molecular Sciences (Online)
SN - 1661-6596
IS - 14
M1 - 11328
ER -
ID: 362061137